Verve PUBLIC | PUBLIC | NASDAQ:VERV Developing therapies to safely edit the adult genome and confer lifelong protection from cardiovascular disease https://www.vervetx.com Press Releases Verve Therapeutics Appoints Cardiologist Andrew Bellinger, M.D., Ph.D., as CSO Oct 3, 2019 Verve Therapeutics Appoints Drug Delivery Expert Andrew Geall, Ph.D., to Scientific Advisory Board Sep 16, 2019 Verve Therapeutics Founded to Protect Against Heart Disease Launches with $58.5 Million in Series A Funding Led by GV May 7, 2019 Press Coverage The Philadelphia Inquirer: 10-year-old’s cholesterol was over 800. Can CRISPR fix the problem? Jun 10, 2019 Medium: Google Cares About your Heart: Verve Therapeutics Explodes out of Stealth Mode May 15, 2019 International Business Times: Google Jumps Into Gene Editing: 5 Things You Need To Know May 13, 2019
Verve Therapeutics Appoints Drug Delivery Expert Andrew Geall, Ph.D., to Scientific Advisory Board Sep 16, 2019
Verve Therapeutics Founded to Protect Against Heart Disease Launches with $58.5 Million in Series A Funding Led by GV May 7, 2019
The Philadelphia Inquirer: 10-year-old’s cholesterol was over 800. Can CRISPR fix the problem? Jun 10, 2019
